TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pharmacokinetics of fruquintinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time with the intragastric pH>4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage time with the intragastric pH>6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: The time of the intragastric pH reaching 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: The time of the intragastric pH reaching 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in days of antibiotic associated diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oldenburger sentence test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: localization test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Symptom Assessment (NSA-16) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Time to Achieve Target Hemoglobin Range (10-12 Gram/Deciliter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Maintaining Hemoglobin Level Within 1 Gram/Deciliter of Baseline Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: biofilm production measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Chronic Respiratory Questionnaire (CRQ) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the effect time curve (EAUC) for insulin, glucose, glucagon, GLP1, C-peptide and GIP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum observed effect (EMax) for insulin, glucose, glucagon, GLP1, C-peptide and GIP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to reach Maximum observed effect (TEMax) for insulin, glucose, glucagon, GLP1, C-peptide and GIP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with clinically significant electrocardiograms (ECGs) abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: difference in microbiome biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation of AVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time duration of biliary recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: p02 value in blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oral Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast-Feeding at Hospital Discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reaction Time Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-regional recurrence-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: SpO2 measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of the ESD procedure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Soft Tissue Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood-based biomarkers of neonatal Hypoxic Ischemic Encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Target concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Participants with All-Cause Mortality at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants who Achieve a Clinical Outcome of Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angles of the joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensibility and specificity for pneumonia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms and functional limitations - Upper limb
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of the gluten free casein free diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the gluten free casein free diet
Endpoint domain: Adverse events/effects
Primary endpoint: Objectively Measured Physical Activity of at Least Moderate Intensity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self Reported Min/Week of MVPA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Muscle sodium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin sodium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for additional potassium-lowering medical interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain upon arrival in the recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical Atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant Adherence to Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerable dose (MTD) of irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment related dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Stunting of Linear Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual lesions after meniscectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of diazepam amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Location of TFH cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of Gestational Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Atrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: One year graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Cotinine-verified quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change of vaginal laxity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of the first psychiatric hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Plasma concentration of Recombinant Human Coagulation Factor VIIa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes of activated partial thromboplastin time (APTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes of prothrombin time (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 100-day survival
Endpoint domain: Mortality/survival
Primary endpoint: Absolute DNT reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum microRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form Health Survey (SF-12) Physical Component Score (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intensity of emotion in medical staff
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intensity of emotion in family
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Empathy scored by Saarbrucken Personality Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Numeric Rating Scale (NRS) pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast biopsy results (malignant or benign)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Histological performance of bone grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Corneal epithelialization after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic effectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD fMRI Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychological impacts of SARS-CoV-2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change From Baseline in Target Area Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5HT7 Serotonin receptor expression on circulating leukocyte cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 5-HT7 Serotonin receptor mRNA quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-HT7 receptor role on lymphocyte functions in vitro
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Declines in oral corticosteroid therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in movement performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TGF-β, Smad6, and Smad7 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Spontaneous life-threatening arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: millimeters of new attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sum of complete responders and partial responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in cardiac ejection fraction by MUGA scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerability of SRX246
Endpoint domain: Adverse events/effects
Primary endpoint: Total amount of radioactivity excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) foliglurax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax foliglurax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL/F foliglurax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total recovery of the administered dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first occurrence of CV death, non-fatal MI, or stent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Probability of Relapse-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with an anti-hepatitis B concentration ≥10 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with an anti-MenC titre ≥1:8 dil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Discontinued Due to Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Histopathological regression of cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: COPD-specific mass spectrometric exhaled breath pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cough Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MIF Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of Calcipotriene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Betamethasone Dipropionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Metabolite MC1080
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External rotation degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-report Measure of Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants with accurate diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Classification of cervical cancer progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of appendage occlusion techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Troponins (cTnI and cTnT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase of Interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pre-dose Morning FEV1 at Week 8 - Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in aortic valve calcium volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Patient Activity Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: antigenic specificity of IV T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: presence of viral RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: expression of inflammatory chemokines/cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: expression of adhesion molecules and scavenger receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Lymphocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Number and Duration of Decompensation Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deformation of the lamina cribrosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the concentration-time curve From Time 0 to 12 Hours Postdose (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incremental recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonfatal acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nonfatal stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hospital admission due to congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour Weighted Mean Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fecal volatile methyl sulfides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent Change in Lactate Dehydrogenase (LDH) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain magnetic resonance imaging lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of high intensity transient signals on transcranial Doppler monitorization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Area of Geographic Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFV concentrations in blood plasma, aspirate and tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFV-DP concentrations in PBMCs, endocervical cells and tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in probing depth in sites with PPD>3mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in probing depth in sites with PPD>5mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in probing depth in sites with CAL>3mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in probing depth in sites with CAL>5mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Meeting Good Sleep Latency Criteria
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Area Under the Absorption Curve for polyphenol preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Device feasibility assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dysmenorrheal Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of complete defaecations per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Unscheduled visits for asthma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of subjects who complete all of the intervention exercises
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who show a decline of >= 1.5 SD from baseline on WAIS-IV Working Memory Score or HVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in peripheral blood and mucosal cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of hypovolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drinking-related negative consequences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: social (interactional) anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxiety levels of child and parent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in peak volume oxygen - VO2 (L/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the minute ventilation/carbon dioxide production (VE/VCO2) slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the respiratory exchange ratio (RER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: safety/feasibility
Endpoint domain: Adverse events/effects
Primary endpoint: Change in back pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of analgosedation dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of stress and anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of PDMP Checks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnosis of Cushing's syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Vitreous NSAIDs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Recurrence of CDI-related Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Physician Empathy Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Who Have Died From Cardiovascular Disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Non Fatal Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Non Fatal Stroke/TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With at Least 1-Grade Improvement at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects